Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C21H30Cl2N2O5
CAS Number:
Molecular Weight:
461.38
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI key
QNQZBKQEIFTHFZ-UHFFFAOYSA-N
SMILES string
CCCCCN(CCCOC)C(=O)C(CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1
InChI
1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)
assay
≥97% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: ≥5 mg/mL
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Loxiglumide is a CCK-A receptor antagonist
Loxiglumide is a small-molecule antagonist of the cholecystokinin receptor CCKA. Loxiglumide inhibits pancreatic secretion of digestive enzymes, and also blocks CCK-induced gastric secretions and emptying.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
T J Little et al.
Obesity reviews : an official journal of the International Association for the Study of Obesity, 6(4), 297-306 (2005-10-26)
Summary Cholecystokinin (CCK), a peptide that is distributed widely throughout the gastrointestinal tract and the central nervous system, has a number of physiological effects including the stimulation of gallbladder contraction and pancreatic and gastric acid secretion, slowing of gastric emptying
Kozo Takase et al.
Nihon rinsho. Japanese journal of clinical medicine, 62(11), 2074-2078 (2004-11-24)
Despite improvement in intensive medical care management, the mortality rate from severe acute pancreatitis is still high. Attempt to reduce the mortality rate, some new drugs were investigated on experimental pancreatitis and clinical cases. There have been several clinical trials
M Rizzo et al.
Journal of pharmaceutical and biomedical analysis, 35(2), 321-329 (2004-04-06)
A high-performance liquid chromatography (HPLC)-method after solid-phase extraction (SPE) has been developed in order to determine a new angiotensin-AT1 antagonist, i.e. CR 3210 (C27H24N8; MW = 460.54), 4-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-3-(2H-tetrazol-5-yl)quinoline in rat plasma and urine after oral administration to Sprague-Dawley rats. CR
Daisuke Kanemitsu et al.
Pancreas, 32(2), 190-196 (2006-03-23)
Prior studies have indicated that endogenous or exogenous cholecystokinin (CCK) induces transient acinar cell proliferation at about 24 hours after its stimulation. The aims of the present study were to determine the time point when the administration of the CCK-A-receptor
L Hidalgo et al.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, 14(5), 519-525 (2002-10-03)
Our aim was determine the relationship between cholecystokinin (CCK)-A receptor blockade, glucose levels, insulin secretion and gastric emptying in humans, and to assess the effect of CCK-A blockade on pancreatic polypeptide secretion. After a 12-h fast, six healthy volunteers were
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service